TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1442491

Group type: EXPERIMENTAL
Intervention: amiodarone plus xamoterol (200 mg two times daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: amiodarone plus metoprolol (50 mg two times daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: amiodarone alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: amiodarone plus xamoterol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: amiodarone plus beta-blockers (metoprolol or xamoterol)
Number of subjects: 20
Study: 2857633

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (0.5 g t.i.d.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: salazosulfapyridine (1.0 g t.i.d.)
Number of subjects: 60
Study: 30646923

Group type: EXPERIMENTAL
Intervention: Program of Social intervention associated with techniques of Domotic and Remote assistance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 0
Study: 29246424

Group type: EXPERIMENTAL
Intervention: Bioactive glass (Biogran) alone (group 1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bioactive glass combined with autogenous bone graft (1:1) (group 2)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Autogenous bone graft alone (group 3)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Bioactive glass and autogenous bone graft (1:1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Bioactive glass alone and autogenous bone graft alone
Number of subjects: 33
Study: 27639163

Group type: EXPERIMENTAL
Intervention: WM training (20 sessions of dual n-back task training for four weeks)
Number of subjects: 34
Study: 25275522

Group type: EXPERIMENTAL
Intervention: Pro-social priming
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-social priming
Number of subjects: 45

Group type: COMPARATOR
Intervention: Anti-social priming
Number of subjects: 45
Study: 21952418

Group type: EXPERIMENTAL
Intervention: Caffeine intervention
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 33

Group type: COMPARATOR
Intervention: Six minute walk test
Number of subjects: 33

Group type: COMPARATOR
Intervention: Endurance shuttle walk test
Number of subjects: 33
Study: 20398993

Group type: EXPERIMENTAL
Intervention: Simulator patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Actor patients
Number of subjects: 12
Study: 18640933

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (bolus and infusion fluorouracil [FU] and leucovorin [LV] with oxaliplatin)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: bFOL (bolus FU and low-dose LV with oxaliplatin)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: CapeOx (capecitabine with oxaliplatin)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus bevacizumab
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: bFOL plus bevacizumab
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: CapeOx plus bevacizumab
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: All treated patients
Number of subjects: 373
Study: 16447879

Group type: EXPERIMENTAL
Intervention: Large dosage of salvia injection (24 ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Middle dosage of salvia injection (16 ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Small dosage of salvia injection (8 ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no salvia injection)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall efficacy of salvia injection
Number of subjects: 120
Study: 12005271

Group type: EXPERIMENTAL
Intervention: Almotriptan 6.25 mg
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 1791

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1791
Study: 19667506

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfonylureas, repaglinide, metformin, acarbose, thiazolidinediones
Number of subjects: 0
Study: 8979780

Group type: EXPERIMENTAL
Intervention: OAM (omeprazole 20 mg daily, amoxycillin 500 mg tid, metronidazole 400 mg tid)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: RAM (ranitidine 600 mg bd, amoxycillin 500 mg tid, metronidazole 400 mg tid)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: OC (omeprazole 20 mg daily, clarithromycin 500 mg tid)
Number of subjects: 80

Group type: COMPARATOR
Intervention: OP (omeprazole 20 mg daily and placebo)
Number of subjects: 80
Study: 1279170

Group type: EXPERIMENTAL
Intervention: Intravenous iloprost (0.5-2.0 ng/kg/min)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 35
Study: 3888335

Group type: EXPERIMENTAL
Intervention: Adjuvant cytotoxic portal vein perfusion
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 244
Study: 31050786

Group type: EXPERIMENTAL
Intervention: Educational attainment (EA)
Number of subjects: 23468

Group type: EXPERIMENTAL
Intervention: Trauma exposure
Number of subjects: 23468

Group type: EXPERIMENTAL
Intervention: Risk-taking behaviors
Number of subjects: 23468

Group type: EXPERIMENTAL
Intervention: Income (Mendelian randomization)
Number of subjects: 23468

Group type: EXPERIMENTAL
Intervention: Multivariable MR income
Number of subjects: 23468

Group type: EXPERIMENTAL
Intervention: Multivariable MR EA
Number of subjects: 23468
Study: 28812132

Group type: EXPERIMENTAL
Intervention: Diet-Restriction-Group (DR)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No-Diet-Restriction-Group (NDR)
Number of subjects: 95
Study: 27243567

Group type: EXPERIMENTAL
Intervention: Group Cognitive Processing Therapy‐Cognitive Only Version
Number of subjects: 108

Group type: COMPARATOR
Intervention: Group Present‐Centered Therapy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Participants who no longer met criteria for PTSD following treatment
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Sleep medication use
Number of subjects: 108
Study: 25903448

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Balance Exercise (BE)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Comparison between AE and BE
Number of subjects: 33
Study: 23930342

Group type: EXPERIMENTAL
Intervention: Academic detailing programme
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (no academic detailing)
Number of subjects: 209
Study: 20603813

Group type: EXPERIMENTAL
Intervention: Adjustment for measurement error in biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from an osteoporosis clinical study
Number of subjects: 0
Study: 18006026

Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 60
Study: 15705230

Group type: EXPERIMENTAL
Intervention: Lyc‐o‐Mato((R)) drink (250 ml daily providing about 6 mg lycopene, 4 mg phytoene, 3 mg phytofluene, 1 mg beta‐carotene, and 1.8 mg alpha‐tocopherol)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 26
Study: 12849805

Group type: EXPERIMENTAL
Intervention: Monitoring with both serum E(2) and ultrasound findings
Number of subjects: 297

Group type: COMPARATOR
Intervention: Monitoring with ultrasound alone
Number of subjects: 297
Study: 10369848

Group type: EXPERIMENTAL
Intervention: Sotalol (160 to 320 mg per day)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 7725845

Group type: EXPERIMENTAL
Intervention: Calcitonin (CT) treatment with 100 IU and 250 mg calcium 3 times a week
Number of subjects: 24

Group type: COMPARATOR
Intervention: Routine thalassemia therapy (Control)
Number of subjects: 24
Study: 2202804

Group type: EXPERIMENTAL
Intervention: Diazepam (0.5 mg/kg, then 0.20 mg/kg, every 12 hours)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 185
Study: 7032343

Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray 200 micrograms b.i.d.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30326770

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (iOT)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 118
Study: 28669111

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gastrografin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Barium sulfate
Number of subjects: 50
Study: 24819432

Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy program (MPP) twice a week (G2: n=58)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy program (MPP) three times a week (G3: n=56)
Number of subjects: 114
Study: 23969334

Group type: EXPERIMENTAL
Intervention: Hinokitiol-containing gel
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control gel (not containing hinokitiol)
Number of subjects: 18
Study: 21834113

Group type: EXPERIMENTAL
Intervention: Pharmacist-Directed Anticoagulation Service (PDAS)
Number of subjects: 500
Study: 19273704

Group type: EXPERIMENTAL
Intervention: Doxorubicin 75 mg/m² every 3 weeks for 6 cycles (arm A)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Doxorubicin 30 mg/m² per day for 3 consecutive days every 2 weeks for 3 cycles followed by ifosfamide 12.5 g/m² over 5 days every 3 weeks for 3 cycles (arm B)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (standard-dose doxorubicin)
Number of subjects: 132
Study: 17902234

Group type: COMPARATOR
Intervention: Self-etching primer (Transbond Plus) with light-cure adhesive (Transbond XT)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Saliva contamination after priming
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Saliva contamination before priming
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Saliva contamination before and after priming
Number of subjects: 240
Study: 15093571

Group type: EXPERIMENTAL
Intervention: Allogeneic-BMT (Allo-BMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous-BMT (A-BMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CCT
Number of subjects: 0
Study: 11552108

Group type: EXPERIMENTAL
Intervention: Warmed intravenous fluids (IVF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonwarmed intravenous fluids
Number of subjects: 20
Study: 9576140

Group type: EXPERIMENTAL
Intervention: Diskus/Accuhaler (DA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Turbuhaler (TH)
Number of subjects: 50
Study: 7867872

Group type: EXPERIMENTAL
Intervention: Twice-weekly thyroxine therapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Daily thyroxine therapy
Number of subjects: 7
Study: 2678692

Group type: EXPERIMENTAL
Intervention: Carotid reconstruction surgery
Number of subjects: 2000
Study: 334212

Group type: EXPERIMENTAL
Intervention: Fenfluramine, 120 mg daily
Number of subjects: 0
Study: 31217353

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-carbohydrate diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 0
Study: 28089729

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (age-matched women without urgency urinary incontinence)
Number of subjects: 0
Study: 25605741

Group type: EXPERIMENTAL
Intervention: Bevacizumab continuation
Number of subjects: 262

Group type: COMPARATOR
Intervention: No continuation of bevacizumab
Number of subjects: 262
Study: 25214451

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (n=16)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (n=15)
Number of subjects: 31
Study: 22773768

Group type: EXPERIMENTAL
Intervention: HYP(BR) - Beetroot juice delivering 0.07 mmol nitrate/kg body wt/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: HYP(CON) - Control drink
Number of subjects: 15
Study: 19375948

Group type: EXPERIMENTAL
Intervention: Partial-breast irradiation (intraoperative radiation therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-breast radiation therapy
Number of subjects: 0
Study: 17970681

Group type: EXPERIMENTAL
Intervention: SRP-D (scaling and root planing with local doxycycline)
Number of subjects: 16

Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 16
Study: 14693787

Group type: EXPERIMENTAL
Intervention: External beam irradiation with five fractions of 3 Gy (total dose 15 Gy)
Number of subjects: 34

Group type: COMPARATOR
Intervention: External beam irradiation with seven fractions of 2 Gy (total dose 14 Gy)
Number of subjects: 34
Study: 11452166

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (600 IU/kg) plus IV iron (n = 29)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (600 IU/kg) plus oral iron (n = 29)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo plus IV iron (n = 25)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo plus oral iron (n = 27)
Number of subjects: 110
Study: 9635707

Group type: COMPARATOR
Intervention: Pelvic radiotherapy alone (45 to 50.4 Gy)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy and bolus 5-fluorouracil-based chemotherapy
Number of subjects: 204
Study: 7977118

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg over 2 minutes, followed by 0.35 mg/kg if needed)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Open-label intravenous diltiazem after placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 2600195

Group type: EXPERIMENTAL
Intervention: Diltiazem 30 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30940760

Group type: EXPERIMENTAL
Intervention: Single high-dose liposomal amphotericin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (WHO recommended first-line treatment)
Number of subjects: 0
Study: 27801550

Group type: EXPERIMENTAL
Intervention: Herring diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Reference diet (chicken and lean pork)
Number of subjects: 15
Study: 26882608

Group type: EXPERIMENTAL
Intervention: Jinying Capsule (JC), 0.5 g per capsule, 4 capsules each time, 3 times per day for 4 weeks
Number of subjects: 328

Group type: COMPARATOR
Intervention: Kangfuyan Capsule (KC), 0.4 g per capsule, 3 capsules each time, twice per day for 4 weeks
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Jinying Capsule (JC)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Kangfuyan Capsule (KC)
Number of subjects: 328
Study: 24260194

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg once daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 21221982

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate/gonadotropin/antagonist (mild protocol)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Microdose GnRH agonist flare (group II)
Number of subjects: 159
Study: 17964822

Group type: EXPERIMENTAL
Intervention: CHIVA (Ambulatory Conservative Haemodynamic Management of Varicose Veins)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saphenous stripping
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CHIVA
Number of subjects: 150
Study: 16931262

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 115

Group type: COMPARATOR
Intervention: Apraclonidine 0.5%
Number of subjects: 115
Study: 12635578

Group type: EXPERIMENTAL
Intervention: Topical nasal fluticasone (50 micrograms per spray, 2 sprays each side every day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Topical nasal fluticasone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11144832

Group type: EXPERIMENTAL
Intervention: Tinnitus Handicap Inventory (THI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tinnitus Questionnaire (TQ)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TQ sleep subscale
Number of subjects: 100
Study: 9570352

Group type: EXPERIMENTAL
Intervention: Tumour-derived tissues from colorectal adenocarcinoma patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum fucose levels in colorectal cancer patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum fucose levels normalized to total protein in colorectal cancer patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fucose levels in relation to Dukes' classification
Number of subjects: 0
Study: 8311273

Group type: COMPARATOR
Intervention: General Anesthesia (GA) with high dose of opioid anesthetic, n = 12
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lumbar Epidural Anesthesia (LEA) to T4 sensory level with light general anesthetic, n = 12
Number of subjects: 24
Study: 3418329

Group type: EXPERIMENTAL
Intervention: High-potency neuroleptics (haloperidol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-potency neuroleptics (chlorpromazine or clozapine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31216128

Group type: EXPERIMENTAL
Intervention: Conventional/light-cured resin composite (Ceram-X)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bulk-fill/light-cured resin composite (SureFil SDR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bulk-fill/dual-cured resin composite (Core-X Flow)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GIC base with resin composites
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: No GIC base with resin composites
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intact teeth
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unrestored teeth
Number of subjects: 30
Study: 28575282

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Number of subjects: 88
Study: 26317629

Group type: EXPERIMENTAL
Intervention: Preoperative Oral Carbohydrate (CHO)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Preoperative Oral Rehydration Solution (ORS)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134

Group type: COMPARATOR
Intervention: Intraoperative vasopressor use
Number of subjects: 134
Study: 23742175

Group type: EXPERIMENTAL
Intervention: Low work surface heights (WSH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher work surface heights (WSH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laboratory workbench at pipette-tip level in standing position with hand at elbow height
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seated posture during pipetting
Number of subjects: 0
Study: 21495078

Group type: EXPERIMENTAL
Intervention: Tai Chi (24 forms simplified)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Stretching and toning exercise (Control)
Number of subjects: 389
Study: 18077730

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg every 12 hours for 14 days
Number of subjects: 2

Group type: COMPARATOR
Intervention: Midazolam 2.0 mg
Number of subjects: 2
Study: 16527008

Group type: EXPERIMENTAL
Intervention: Endoscopic repair using a transantral approach
Number of subjects: 9

Group type: COMPARATOR
Intervention: Transconjunctival repair
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison of endoscopic repair and transconjunctival repair
Number of subjects: 9
Study: 12589525

Group type: EXPERIMENTAL
Intervention: Caffeinated drink (100 mg caffeine)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Decaffeinated drink (placebo)
Number of subjects: 48
Study: 10880013

Group type: EXPERIMENTAL
Intervention: Adenoviral vector delivered intraperitoneally (i.p.) at varying doses (2 x 10(10) to 2 x 10(13) vector particles) with concomitant topotecan chemotherapy and acyclovir.
Number of subjects: 10
Study: 9083284

Group type: EXPERIMENTAL
Intervention: Amino acid administration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (non-treated)
Number of subjects: 12
Study: 8252937

Group type: EXPERIMENTAL
Intervention: Amrinone (1.5 mg/kg loading dose plus 10 micrograms/kg/min maintenance infusion; n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 39
Study: 3828182

Group type: EXPERIMENTAL
Intervention: Extradural infusion of 0.125% bupivacaine (Marcain) 10 ml (12.5 mg) per hour during labour
Number of subjects: 100

Group type: COMPARATOR
Intervention: No infusion (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Extradural infusion of 0.125% bupivacaine (Marcain)
Number of subjects: 100
Study: 29549891

Group type: EXPERIMENTAL
Intervention: Acupuncture (ACP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham acupuncture (SACP)
Number of subjects: 30
Study: 26538631

Group type: EXPERIMENTAL
Intervention: Urine NGAL/creatinine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine KIM-1/creatinine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine IL-18/creatinine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine L-FABP
Number of subjects: 0
Study: 25262252

Group type: EXPERIMENTAL
Intervention: Enhanced and prolonged Holter ECG monitoring (10 days at baseline and after 3 and 6 months)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard of care (≥24‐hour continuous ECG monitoring)
Number of subjects: 400
Study: 22959497

Group type: EXPERIMENTAL
Intervention: High-glycemic load diet
Number of subjects: 89

Group type: COMPARATOR
Intervention: Low-glycemic load diet
Number of subjects: 89
Study: 20014353

Group type: EXPERIMENTAL
Intervention: Local intervention effect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Testing group mean difference
Number of subjects: 0
Study: 18199022

Group type: EXPERIMENTAL
Intervention: Arnica D4 10 pillules (taken orally, 3 times per day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: diclofenac sodium, 50 mg (taken orally, 3 times per day)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Arnica D4
Number of subjects: 88
Study: 15728371

Group type: EXPERIMENTAL
Intervention: Three doses of transgenic potatoes (100 g of tuber, HBsAg at approximately 8.5 microg/g)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Two doses of transgenic potatoes (100 g of tuber, HBsAg at approximately 8.5 microg/g)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nontransgenic potatoes (control group)
Number of subjects: 50
Study: 12947369

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg orally 3 times daily for 2 days)
Number of subjects: 23